BZPEERReading, trust and collaboration for research
Menu

Discover

GraphFollow connections around a paper, topic or saved view.

Workspaces

HomePick up where your research flow left off.InboxHandle requests, replies and notifications from one place.CollectionsCurate reading lists, evidence sets and shareable dossiers.ResearchSee your private provenance graph, trail and imports.CollaborationMove from discovery into focused discussion rooms.PublishDraft, preview and publish full-text research articles.

Network

ExpertsFind specialists worth following or asking for help.CommunitiesJoin research circles organized around shared work.PartnersSee external organizations active around the same topics.

Opportunities

ListingsBrowse roles, calls and collaborations with clearer fit signals.

Account

Log inReturn to your reading and collaboration workspace.Create accountStart saving work, following people and joining teams.
Log inCreate account

Researcher profile

Christian Röver

Christian Röver contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate
MethodologyApplicationsComputation

Trust snapshot

Quick read

Trust 21 - EmergingVerification L1Unclaimed author
6works
0followers
3topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

6 published item(s)

preprint2022arXiv

A straightforward meta-analysis approach for oncology phase I dose-finding studies

Phase I early-phase clinical studies aim at investigating the safety and the underlying dose-toxicity relationship of a drug or combination. While little may still be known about the compound's properties, it is crucial to consider quantitative information available from any studies that may have been conducted previously on the same drug. A meta-analytic approach has the advantages of being able to properly account for between-study heterogeneity, and it may be readily extended to prediction or shrinkage applications. Here we propose a simple and robust two-stage approach for the estimation of maximum tolerated dose(s) (MTDs) utilizing penalized logistic regression and Bayesian random-effects meta-analysis methodology. Implementation is facilitated using standard R packages. The properties of the proposed methods are investigated in Monte-Carlo simulations. The investigations are motivated and illustrated by two examples from oncology.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

Double arcsine transform not appropriate for meta-analysis

The variance-stabilizing Freeman-Tukey double arcsine transform was originally proposed for inference on single proportions. Subsequently, its use has been suggested in the context of meta-analysis of proportions. While some erratic behaviour has been observed previously, here we point out and illustrate general issues of monotonicity and invertibility that make this transform unsuitable for meta-analysis purposes.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

MetaStan: An R package for Bayesian (model-based) meta-analysis using Stan

Meta-analysis methods are used to combine evidence from multiple studies. Meta-regression as well as model-based meta-analysis are extensions of standard pairwise meta-analysis in which information about study-level covariates and (arm-level) dosing amount or exposure may be taken into account. A Bayesian approach to inference is very attractive in this context, especially when a meta-analysis is based on few studies only or rare events. In this article, we present the R package MetaStan which implements a wide range of pairwise and model-based meta-analysis models. A generalised linear mixed model (GLMM) framework is used to describe the pairwise meta-analysis, meta-regression and model-based meta-analysis models. Within the GLMM framework, the likelihood and link functions are adapted to reflect the nature of the data. For example, a binomial likelihood with a logit link is used to perform a meta-analysis based on datasets with dichotomous endpoints. Bayesian computations are conducted using Stan via the rstan interface. Stan uses a Hamiltonian Monte Carlo sampler which belongs to the family of Markov chain Monte Carlo methods. Stan implementations are done by using suitable parametrizations to ease computations. The user-friendly R package MetaStan, available on CRAN, supports a wide range of pairwise and model-based meta-analysis models. MetaStan provides fitting functions for pairwise meta-analysis with the option of including covariates and model-based meta-analysis. The supported outcome types are continuous, binary, and count. Forest plots for the pairwise meta-analysis and dose-response plots for the model-based meta-analysis can be obtained from the package. The use of MetaStan is demonstrated through clinical examples.

0 citations0 reviewsNo code linkedOpen access
preprint2018arXiv

Bayesian random-effects meta-analysis using the bayesmeta R package

The random-effects or normal-normal hierarchical model is commonly utilized in a wide range of meta-analysis applications. A Bayesian approach to inference is very attractive in this context, especially when a meta-analysis is based only on few studies. The bayesmeta R package provides readily accessible tools to perform Bayesian meta-analyses and generate plots and summaries, without having to worry about computational details. It allows for flexible prior specification and instant access to the resulting posterior distributions, including prediction and shrinkage estimation, and facilitating for example quick sensitivity checks. The present paper introduces the underlying theory and showcases its usage.

0 citations0 reviewsNo code linkedOpen access
preprint2018arXiv

Dynamically borrowing strength from another study through shrinkage estimation

Meta-analytic methods may be used to combine evidence from different sources of information. Quite commonly, the normal-normal hierarchical model (NNHM) including a random-effect to account for between-study heterogeneity is utilized for such analyses. The same modeling framework may also be used to not only derive a combined estimate, but also to borrow strength for a particular study from another by deriving a shrinkage estimate. For instance, a small-scale randomized controlled trial could be supported by a non-randomized study, e.g. a clinical registry. This would be particularly attractive in the context of rare diseases. We demonstrate that a meta-analysis still makes sense in this extreme two-study setup, as illustrated using a recent trial and a clinical registry in Creutzfeld-Jakob disease. Derivation of a shrinkage estimate within a Bayesian random-effects meta-analysis may substantially improve a given estimate even based on only a single additional estimate while accounting for potential effect heterogeneity between the studies. Alternatively, inference may equivalently be motivated via a model specification that does not require a common overall mean parameter but considers the treatment effect in one study, and the difference in effects between the studies. The proposed approach is quite generally applicable to combine different types of evidence originating e.g. from meta-analyses or individual studies. An application of this more general setup is provided in immunosuppression following liver transplantation in children.

0 citations0 reviewsNo code linkedOpen access
preprint2018arXiv

Meta-analysis of few studies involving rare events

Meta-analyses of clinical trials targeting rare events face particular challenges when the data lack adequate numbers of events for all treatment arms. Especially when the number of studies is low, standard meta-analysis methods can lead to serious distortions because of such data sparsity. To overcome this, we suggest the use of weakly informative priors (WIP) for the treatment effect parameter of a Bayesian meta-analysis model, which may also be seen as a form of penalization. As a data model, we use a binomial-normal hierarchical model (BNHM) which does not require continuity corrections in case of zero counts in one or both arms. We suggest a normal prior for the log odds ratio with mean 0 and standard deviation 2.82, which is motivated (1) as a symmetric prior centred around unity and constraining the odds ratio to within a range from 1/250 to 250 with 95 % probability, and (2) as consistent with empirically observed effect estimates from a set of $\mbox{$37\,773$}$ meta-analyses from the Cochrane Database of Systematic Reviews. In a simulation study with rare events and few studies, our BNHM with a WIP outperformed a Bayesian method without a WIP and a maximum likelihood estimator in terms of smaller bias and shorter interval estimates with similar coverage. Furthermore, the methods are illustrated by a systematic review in immunosuppression of rare safety events following paediatric transplantation. A publicly available $\textbf{R}$ package, $\texttt{MetaStan}$, is developed to automate the $\textbf{Stan}$ implementation of meta-analysis models using WIPs.

0 citations0 reviewsNo code linkedOpen access